Literature DB >> 9852968

Analysis of the glycoproteins I and E of varicella-zoster virus (VZV) using deletional mutations of VZV cosmids.

S Mallory1, M Sommer, A M Arvin.   

Abstract

The contributions of the glycoproteins gI (ORF67) and gE (ORF68) to varicella-zoster virus (VZV) replication were investigated in deletion mutants made by using cosmids with VZV DNA derived from the Oka strain. These experiments demonstrated that gI was not required for VZV replication in vitro but gE appeared to be. Although VZV gI was not required, its deletion or mutation resulted in a significant decrease in infectious virus yields, and it disrupted syncytial formation and altered the conformation and distribution of gE in infected cells. Normal cell-to-cell spread and replication kinetics were restored when gI was expressed from a non-native locus in the VZV genome. The expression of intact gI, the ORF67 gene product, is required for efficient VZV replication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9852968     DOI: 10.1086/514277

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Marek's disease virus expresses multiple UL44 (gC) variants through mRNA splicing that are all required for efficient horizontal transmission.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Responses of herpes simplex virus type 1-infected cells to the presence of extracellular antibodies: gE-dependent glycoprotein capping and enhancement in cell-to-cell spread.

Authors:  Syed Monem Rizvi; Malini Raghavan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection.

Authors:  Anne Schaap; Jean-Francois Fortin; Marvin Sommer; Leigh Zerboni; Shaye Stamatis; Chia-Chi Ku; Garry P Nolan; Ann M Arvin
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Simian varicella virus gene expression during acute and latent infection of rhesus macaques.

Authors:  Christine Meyer; Amelia Kerns; Alex Barron; Craig Kreklywich; Daniel N Streblow; Ilhem Messaoudi
Journal:  J Neurovirol       Date:  2011-11-04       Impact factor: 2.643

5.  Glycoproteins E and I of Marek's disease virus serotype 1 are essential for virus growth in cultured cells.

Authors:  D Schumacher; B K Tischer; S M Reddy; N Osterrieder
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor.

Authors:  Zhen Zhang; Anca Selariu; Charles Warden; Grace Huang; Ying Huang; Oluleke Zaccheus; Tong Cheng; Ningshao Xia; Hua Zhu
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

7.  Functions of Varicella-zoster virus ORF23 capsid protein in viral replication and the pathogenesis of skin infection.

Authors:  Vaishali Chaudhuri; Marvin Sommer; Jaya Rajamani; Leigh Zerboni; Ann M Arvin
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

8.  A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9.

Authors:  B Karsten Tischer; Benedikt B Kaufer; Marvin Sommer; Felix Wussow; Ann M Arvin; Nikolaus Osterrieder
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

9.  The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11.

Authors:  Jens von Einem; Janet Wellington; J Millar Whalley; Kerstin Osterrieder; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of Varicella-Zoster virus.

Authors:  Randall J Cohrs; Donald H Gilden; Yasuyuki Gomi; Koichi Yamanishi; Jeffrey I Cohen
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.